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Epidemiological studies suggest that both moderate and severe 
hypertriglyceridemia are associated with increased long term cardiovascular risk and 
mortality. Interestingly, the Reduction of Cardiovascular Events with Icosapent Ethyl–
Intervention (REDUCE-IT) randomized trial recently enrolled 8179 statin-treated patients 
with elevated triglycerides levels (135mg/dL and <500mg/dL) and either established 
cardiovascular disease or diabetes plus at least one risk factor, and demonstrated that high 
dose (4 g/day) of icosapent ethyl reduced the risk of ischemic events, including 
cardiovascular death (1). Indeed, the secondary prevention cohort represented 70.7% of the 
total cohort, which experienced a lower rate of the key secondary efficacy composite 
endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke as 
compared to the placebo group (12.5% vs 16.9% HR:0.72, 95%CI (0.63-0.82). 
Using a large contemporary international cohort of patients with stable coronary 
artery disease, we sought to evaluate what proportion of patients would be potentially 
eligible for enrollment. The CLARIFY (ProspeCtive observational LongitudinAl RegIstry 
oF patients with stable coronary arterY disease) registry is an international prospective 
observational longitudinal registry that has been previously described (2). Briefly, stable 
coronary artery disease (CAD) patients from 45 countries were enrolled between 
November 2009 and June 2010. The inclusion criteria were any of the following: previous 
myocardial infarction, evidence of coronary stenosis >50%, proven symptomatic 
myocardial ischemia, or prior coronary revascularization procedure.  Follow-up visits were 
planned annually for up to 5 years.  
The REDUCE-IT selection criteria were applied to CLARIFY patients. Key 
inclusion criteria included statin-treated men or women age ≥45 years with either 
established cardiovascular disease or age ≥50 years with diabetes mellitus in combination 
with at least one additional risk factor for cardiovascular disease, with triglycerides levels 
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135mg/dL and 500 mg/dL, and low density lipoprotein (LDL)-cholesterol >40mg/dL 
and 100 mg/dL (1). In the REDUCE-IT trial, patients were excluded if they had severe 
heart failure, active severe liver disease, a glycated hemoglobin level greater than 10.0%, a 
planned coronary intervention or surgery, a history of acute or chronic pancreatitis, or 
known hypersensitivity to fish, shellfish, or ingredients of icosapent ethyl or placebo (1). 
As data on exclusion criteria were not all recorded in the CLARIFY registry, they were not 
included to the present analysis.  
In CLARIFY, 24,146 out of 32,703 patients had complete data (505 patients with 
missing triglycerides dosage) allowing evaluation of eligibility. Overall, 15.5% 
(3738/24146 patients) were eligible for enrollment in REDUCE-IT. Among those not 
eligible, 3.8% of the patients (n=926) were younger than 45 years, 57.1% (n=13791) had 
triglyceride levels<135mg/dL, 0.6% (n=144) had levels500mg/dL, and 47.0% (n=11 342) 
of patients did not fulfil the LDL-cholesterol inclusion criteria (12.6% [n=3034] had LDL-
cholesterol40mg/dL and 34.4% [n=8308]>100 mg/dL). 
 Our study demonstrates that in a large international registry, 15.5% of patients with 
stable coronary artery disease met the REDUCE-IT inclusion criteria, thus being eligible 
for treatment with icosapent ethyl to reduce cardiovascular risk. The most frequent reasons 
for non-eligibility were triglycerides<135mg/dL (57.1%) and LDL-cholesterol>100mg/dL 
(34.4%), which may depend on lifestyle and adherence to evidence-based recommended 
intensive statin therapy, which are likely to vary across geographic regions. Global data 
indicate there are approximately 110.55 million patients with stable CAD similar to the 
definition in CLARIFY.(3) If 15.5% of these patients are eligible for icosapent ethyl, that 
works out to approximately 17.14 million patients who may benefit. On the basis of data 
from the National Health and Nutrition Examination Survey from 2011 to 2014, an 
estimated 16.5 million Americans have CAD, which translates in a prevalence of 6.3% in 
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American adults. (4) Therefore, 15.5% of 16.5 million represent 2.56 million American 
adults who could benefit from such treatment. Of note, the CLARIFY registry did not 
include patients from the United States, where the prevalence of high triglycerides and the 
use of intensive statin treatment are likely higher than in other parts of the world, and 
therefore where eligibility may be more frequent. In addition, the REDUCE-IT trial also 
enrolled patients with peripheral artery disease or cerebrovascular disease as well as 
patients with diabetes mellitus and an additional cardiovascular risk factor, and therefore 
has a much broader recruitment base than solely stable CAD patients as in CLARIFY.  
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Figure Legend 
Figure: Frequency of the various non-inclusion criteria ranked by descending order of 
frequency. In the CLARIFY registry, 15.5% (3738/24146 patients) were eligible for enrollment in 
REDUCE-IT. Among those not eligible, 3.8% of the patients (n=926) were younger than 45 years, 57.1% 
(n=13791) had triglyceride levels<135mg/dL, 0.6% (n=144) had levels500mg/dL, and 47.0% (n=11 342) 
of patients did not fulfil the LDL-cholesterol inclusion criteria (12.6% [n=3034] had LDL-
cholesterol40mg/dL and 34.4% [n=8308]>100 mg/dL). 
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